Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Blood (2024) 144 (Supplement 1): 805.

https://doi.org/10.1182/blood-2024-204230

Published: 2024

Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 459.

https://doi.org/10.1182/blood-2024-204113

Published: 2024

Journal Articles

High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease

Mitali Sen, Gordon J Ruan, Samuel B Reynolds, Haadi Ali, XI Yang, Diana Morlote, Aishwarya Ravindran, Lauren Kelly Shea, Matthew J Koster, Jithma P Abeykoon, Hind Salama, Xinxin Cao, Asra Z. Ahmed, Ronald S Go, Gaurav Goyal

Blood (2024) 144 (Supplement 1): 3910.

https://doi.org/10.1182/blood-2024-201817

Published: 2024

Journal Articles

Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Alanis Enid Rodriguez-Rosario, Aldo Adrian Acosta Medina, N. Nora Bennani, Gaurav Goyal, Aishwarya Ravindran, Karen L Rech, Gordon J Ruan, Mithun V Shah, Dongni Yi, Saurabh Zanwar, Jithma P Abeykoon, Ronald S Go

Blood (2024) 144 (Supplement 1): 4564.

https://doi.org/10.1182/blood-2024-205474

Published: 2024

Journal Articles

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis

Blood (2024) 144 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2024-204398

Published: 2024

Journal Articles

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Adi Zoref-Lorenz, Elliot J Cahn, Eric Mou, Yucai Wang, Matthew J. Maurer, Andrew L. Feldman, Bri J Negaard, Raphael Mwangi, Gilad Itchaki, Grzegorz S. Nowakowski, Thomas M. Habermann, Brian K. Link, Stephen M. Ansell, Anne J. Novak, Gaurav Goyal, Thomas E. Witzig, James R. Cerhan, Michael B. Jordan

Blood (2024) 144 (Supplement 1): 1624.

https://doi.org/10.1182/blood-2024-210119

Published: 2024

Journal Articles

Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms

Blood (2024) 144 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2024-193841

Published: 2024

Journal Articles

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Mayur S. Narkhede, Antonio Di Stasi, Lauren Kelly Shea, Susan Bal, Gayathri Ravi, Gaurav Goyal, Pamela Hardwick, Smith Giri, Donna Salzman, Ravi Bhatia, Luciano J. Costa, Amitkumar Mehta

Blood (2024) 144 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2024-205205

Published: 2024

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 570.

https://doi.org/10.1182/blood-2024-199845

Published: 2024

Journal Articles

Adult Langerhans Cell Histiocytosis with Liver Involvement

Long Chang, Lin He, Huacong Cai, Minghui Duan, Jian Li, Daobin Zhou, Gaurav Goyal, Xinxin Cao

Blood (2023) 142 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2023-184790

Published: 2023

Journal Articles

Cardiovascular Morbidity in Erdheim-Chester Disease (ECD) Patients with and without Cardiac Involvement

Reema K Tawfiq, Jason R Young, Madeline Mahowald, Saurabh Zanwar, Gordon J Ruan, Karen L Rech, Matthew J Koster, Lucinda Gruber, Aishwarya Ravindran, Mithun V Shah, N. Nora Bennani, Robert Vassallo, Jay Ryu, Caroline Davidge-Pitts, Surendra Dasari, Thomas E. Witzig, Ronald S. Go, Gaurav Goyal, Jithma Prasad Abeykoon

Blood (2023) 142 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2023-180322

Published: 2023

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Journal Articles

Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease

Gaurav Goyal, Anne Reiner, Dana Bossert, Allison Sigler, Justin Buthorn, Mario Lacouture, Veronica Rotemberg, Jasmine H Francis, Ronald S. Go, Raajit K. Rampal, Eli L. Diamond

Blood (2023) 142 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2023-184879

Published: 2023

Journal Articles

Factors Affecting Health-Related Quality of Life Among Individuals with Histiocytic Neoplasms

David Pottinger, Matthew Slief, Ene Enogela, Jithma Prasad Abeykoon, Saurabh Zanwar, Gordon J Ruan, Rachelle Rouse, Baylie Mullinax, Kathleen Brewer, Deanna Fournier, Aishwarya Ravindran, Diana Morlote, Samuel Hand, Maria D Acosta Lara, Richard Taylor, Abby McCrory, Anita D'Souza, Ronald S. Go, Gaurav Goyal

Blood (2023) 142 (Supplement 1): 6394.

https://doi.org/10.1182/blood-2023-178372

Published: 2023

Journal Articles

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Blood (2023) 142 (18): 1570–1575.

https://doi.org/10.1182/blood.2023021212

Published: 2023

Includes: Supplemental data

Journal Articles

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2023-188829

Published: 2023

Journal Articles

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2023-184911

Published: 2023

Journal Articles

Molecular Findings on Plasma Cell-Free DNA Analysis Among Adults with Histiocytic Neoplasms

Blood (2023) 142 (Supplement 1): 6332.

https://doi.org/10.1182/blood-2023-187500

Published: 2023

Journal Articles

Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study

Gordon Ruan, Jithma P. Abeykoon, Aldo A. Acosta Medina, Saurabh Zanwar, Aishwarya Ravindran, Karen Rech, Jason R. Young, Jay Ryu, Matthew Koster, W. Oliver Tobin, Mithun V. Shah, N. Nora Bennani, Robert Vassallo, Baylie Brooks, Ginny-Tyler Meadows, Abby McCrory, Diana Morlote, Gaurav Goyal, Ronald Go

Blood (2022) 140 (Supplement 1): 3995–3996.

https://doi.org/10.1182/blood-2022-159714

Published: 2022

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

NARROW

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease

Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis

Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Adult Langerhans Cell Histiocytosis with Liver Involvement

Cardiovascular Morbidity in Erdheim-Chester Disease (ECD) Patients with and without Cardiac Involvement

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease

Factors Affecting Health-Related Quality of Life Among Individuals with Histiocytic Neoplasms

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society

Molecular Findings on Plasma Cell-Free DNA Analysis Among Adults with Histiocytic Neoplasms

Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only